SG81976A1 - Substituted tricyclics - Google Patents

Substituted tricyclics

Info

Publication number
SG81976A1
SG81976A1 SG9901681A SG1999001681A SG81976A1 SG 81976 A1 SG81976 A1 SG 81976A1 SG 9901681 A SG9901681 A SG 9901681A SG 1999001681 A SG1999001681 A SG 1999001681A SG 81976 A1 SG81976 A1 SG 81976A1
Authority
SG
Singapore
Prior art keywords
substituted tricyclics
tricyclics
substituted
Prior art date
Application number
SG9901681A
Other languages
English (en)
Inventor
Benjamin Alan Anderson
Nicholas James Bach
Jolie Anne Bastian
Nancy Kay Harn
Richard Waltz Harper
Gary Alan Hite
Michael Dean Kinnick
Ho-Shen Lin
Richard James Loncharich
John Mcneill Mcgill Iii
Edward David Mihelich
John Michael Junior Morin
Michael Leroy Phillips
Michael Enrico Richett
Daniel Jon Sall
Jason Scott Sawyer
Richard Walter Schevitz
Robert Theodore Vasileff
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG81976A1 publication Critical patent/SG81976A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG9901681A 1998-04-17 1999-04-16 Substituted tricyclics SG81976A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
SG81976A1 true SG81976A1 (en) 2001-07-24

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
SG9901869A SG81977A1 (en) 1998-04-17 1999-04-16 Substituted tricyclics
SG9901681A SG81976A1 (en) 1998-04-17 1999-04-16 Substituted tricyclics

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG9901869A SG81977A1 (en) 1998-04-17 1999-04-16 Substituted tricyclics

Country Status (30)

Country Link
EP (2) EP0950657B1 (ja)
JP (2) JP4435330B2 (ja)
KR (2) KR100586761B1 (ja)
CN (1) CN1149193C (ja)
AR (2) AR018186A1 (ja)
AT (2) ATE268756T1 (ja)
AU (2) AU753436B2 (ja)
BR (2) BR9901279A (ja)
CA (2) CA2269262A1 (ja)
CO (2) CO5011054A1 (ja)
CZ (2) CZ136999A3 (ja)
DE (2) DE69918590T2 (ja)
DK (1) DK0950657T3 (ja)
DZ (1) DZ2769A1 (ja)
EA (2) EA002816B1 (ja)
ES (2) ES2226286T3 (ja)
HU (2) HUP9901220A3 (ja)
ID (2) ID23287A (ja)
IL (2) IL129483A0 (ja)
NO (2) NO312240B1 (ja)
NZ (3) NZ335251A (ja)
PE (2) PE20000432A1 (ja)
PL (2) PL332566A1 (ja)
PT (1) PT950657E (ja)
SG (2) SG81977A1 (ja)
SI (1) SI0950657T1 (ja)
TR (2) TR199900853A2 (ja)
TW (1) TWI238160B (ja)
YU (2) YU19199A (ja)
ZA (2) ZA992771B (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9123198A (en) * 1997-08-28 1999-03-16 Eli Lilly And Company Method for treatment of non-rheumatoid athritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
JP2002542148A (ja) * 1998-12-21 2002-12-10 イーライ・リリー・アンド・カンパニー 敗血症の処置のための組み合わせ療法
EP1202963B1 (en) * 1999-07-19 2007-01-03 Eli Lilly And Company Spla2 inhibitors
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
ES2294003T3 (es) * 2000-06-29 2008-04-01 Anthera Pharmaceuticals, Inc. Remedios contra el cancer.
AU2001267825A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
WO2002000257A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes a la maladie d'alzheimer
WO2002005796A2 (en) * 2000-07-14 2002-01-24 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
EP1345898A2 (en) 2000-12-18 2003-09-24 Eli Lilly And Company Teracyclic carbazole derivates and their use as spla2 inhibitors
ATE353876T1 (de) * 2001-03-28 2007-03-15 Lilly Co Eli Substituierte carbazole als inhibitoren von spla2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
KR20100124771A (ko) 2008-03-26 2010-11-29 다이이찌 산쿄 가부시키가이샤 신규 테트라하이드로이소퀴놀린 유도체
JP5637982B2 (ja) 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ， インコーポレイテッド 脂肪酸アミド加水分解酵素の阻害剤
EP2379538A4 (en) 2009-01-22 2013-01-02 Orchid Res Lab Ltd HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER
EP2417115A4 (en) 2009-04-07 2012-10-31 Infinity Pharmaceuticals Inc FATTY ACID AMIDE HYDROLASE INHIBITORS
AU2010234445A1 (en) 2009-04-07 2011-11-03 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
KR101888026B1 (ko) 2010-02-03 2018-08-13 인피니티 파마슈티컬스, 인코포레이티드 지방산 아미드 하이드롤라제 저해제
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
BR112015012138A2 (pt) 2012-11-30 2017-07-11 Ge Healthcare Ltd composição, método para obtenção de uma composição, método de formação de imagem in vivo, e, kit
KR20150088803A (ko) * 2012-11-30 2015-08-03 지이 헬쓰케어 리미티드 트리시클릭 인돌을 생성하는 아연 할라이드 매개 고리화 방법
WO2016116527A1 (de) * 2015-01-20 2016-07-28 Cynora Gmbh Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
EP0839806A1 (en) * 1996-10-30 1998-05-06 Eli Lilly And Company Substituted tricyclics
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
CA2110514A1 (en) * 1991-07-05 1993-01-21 Raymond Baker Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
CA2179678A1 (en) * 1995-06-23 1996-12-24 Michael Edward Flaugh 6-substituted-1,2,3,4-tetrahydro-9h-carbazoles and 7-substituted-10h-cyclohepta¬7,6-b| indoles
US6160175A (en) * 1995-12-13 2000-12-12 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
EP0839806A1 (en) * 1996-10-30 1998-05-06 Eli Lilly And Company Substituted tricyclics
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
WO1999025340A1 (en) * 1997-11-14 1999-05-27 Eli Lilly And Company Treatment for alzheimer's disease

Also Published As

Publication number Publication date
HU9901221A (hu) 2000-04-28
KR19990083233A (ko) 1999-11-25
ES2222663T3 (es) 2005-02-01
HUP9901221A3 (en) 2001-11-28
PL332565A1 (en) 1999-10-25
EP0950657B1 (en) 2004-07-14
ATE268756T1 (de) 2004-06-15
CO5031247A1 (es) 2001-04-27
NZ335251A (en) 2000-11-24
CA2269262A1 (en) 1999-10-17
NO991821D0 (no) 1999-04-16
SG81977A1 (en) 2001-07-24
CZ136999A3 (cs) 1999-11-17
AU2381799A (en) 1999-10-28
EP0950657A3 (en) 2001-08-16
PE20000476A1 (es) 2000-06-02
TR199900853A3 (tr) 1999-11-22
AU753547B2 (en) 2002-10-24
NZ335253A (en) 2000-11-24
ZA992772B (en) 2002-07-16
DE69918590D1 (de) 2004-08-19
EA002347B1 (ru) 2002-04-25
NO312240B1 (no) 2002-04-15
TWI238160B (en) 2005-08-21
CZ137099A3 (cs) 1999-11-17
HU9901221D0 (en) 1999-06-28
ID23761A (id) 2000-05-11
PE20000432A1 (es) 2000-05-23
DE69918590T2 (de) 2005-07-21
EA199900303A2 (ru) 1999-10-28
KR19990083232A (ko) 1999-11-25
NZ507564A (en) 2002-10-25
HU9901220A (hu) 2000-04-28
YU18999A (sh) 2002-08-12
NO314400B1 (no) 2003-03-17
BR9902365A (pt) 2001-04-24
EP0952149B1 (en) 2004-06-09
ES2226286T3 (es) 2005-03-16
DZ2769A1 (fr) 2003-12-01
TR199900843A2 (xx) 2000-02-21
ZA992771B (en) 2002-04-18
HUP9901220A3 (en) 2001-11-28
NO991822L (no) 1999-10-18
PL332566A1 (en) 1999-10-25
JPH11322713A (ja) 1999-11-24
AU2381999A (en) 1999-10-28
AR018186A1 (es) 2001-10-31
EP0950657A2 (en) 1999-10-20
CA2269246C (en) 2009-08-25
NO991821L (no) 1999-10-18
EP0952149A2 (en) 1999-10-27
CN1149193C (zh) 2004-05-12
KR100586761B1 (ko) 2006-06-08
NO991822D0 (no) 1999-04-16
CO5011054A1 (es) 2001-02-28
BR9901279A (pt) 2000-05-02
EA199900301A3 (ru) 2000-04-24
AU753436B2 (en) 2002-10-17
HU9901220D0 (en) 1999-06-28
EA002816B1 (ru) 2002-10-31
EA199900303A3 (ru) 2000-04-24
JP2000026416A (ja) 2000-01-25
EP0952149A3 (en) 2001-08-16
DE69917833D1 (de) 2004-07-15
JP4435330B2 (ja) 2010-03-17
EA199900301A2 (ru) 1999-10-28
IL129483A0 (en) 2000-02-29
AR018593A1 (es) 2001-11-28
CN1253948A (zh) 2000-05-24
CA2269246A1 (en) 1999-10-17
TR199900853A2 (xx) 1999-11-22
PT950657E (pt) 2004-11-30
YU19199A (sh) 2002-08-12
ID23287A (id) 2000-04-05
DK0950657T3 (da) 2004-11-22
DE69917833T2 (de) 2005-07-14
SI0950657T1 (en) 2005-02-28
IL129485A0 (en) 2000-02-29
ATE271037T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
IL129483A0 (en) Substituted tricyclics
DE59912932D1 (en) Arylphenylsubstituierte cyclische ketoenole
DE59912303D1 (en) Arylphenylsubstituierte cyclische ketoenole
GB2342193B (en) Addition circuitry
PL341642A1 (en) Novel macrolydes
DE69904335D1 (en) Aminomethylcarbonsäurederivate
DE69835235D1 (en) Thermoplastische silikonelastomere
DE59903023D1 (en) Perorale wirkstoff-suspension
IL129481A0 (en) Substituted tricyclics
DE59914151D1 (en) Arylalkanoylpyridazine
IL129484A0 (en) Substituted tricyclics
EP1068213A4 (en) SILOXANES WITH AMINO-ORGANIC FUNCTIONAL GROUP
DE60042897D1 (en) Photovervielfacherröhre
DE59904407D1 (en) Chromanderivate
GB9816729D0 (en) Substituted cyclohexylaminopyrimidines
HK1039937A1 (zh) 取代的3-硫代氨基甲酰基吡唑類化合物
DE69821502D1 (en) Boroskop
PL347397A1 (en) Substituted 3-aryl-pyrazoles
DE59900495D1 (en) Multimetalloxidmassen
DE59900471D1 (en) Inchbremseinrichtung
HUP0102476A3 (en) Substituted cyclooctadepsipeptides
HK1039335A1 (zh) 取代的苯甲酰基環已二酮類化合物
DE69902586D1 (en) Expandierte ethylencopolymere
DE59905941D1 (en) Methoximinophenylessigsäureamide
DE59911094D1 (en) Tryptase-inhibitoren